[Rituximab treatment of rheumatoid arthritis: new evidence].
New evidence is reviewed on efficacy and safety of chimeric monoclonal antibodies to B-cell CD20 molecule (rituximab) in the treatment of rheumatoid arthritis.
Nasonov
E L
EL
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007555:Isoxazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077339:Leflunomide; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D018501:Antirheumatic Agents; D007555:Isoxazoles; D000069283:Rituximab; D000077339:Leflunomide; D008727:Methotrexate